Piper bullish on Novavax in preparket analyst action

|By:, SA News Editor

Audentes Therapeutics (NASDAQ:BOLD) initiated with Overweight rating and $35 (46% upside) price target at JPMorgan.

CytomX Therapeutics (NASDAQ:CTMX) initiated with Overweight rating and $22 (66% upside) price target at Piper Jaffray.

Stemline Therapeutics (NASDAQ:STML) initiated with Overweight rating at Piper.

Twist Bioscience (NASDAQ:TWST) initiated with Outperform rating and $30 (15% upside) price target at Baird. Initiated with Outperform rating at Piper. Initiated with Neutral rating at JPMorgan.

Orchard Therapeutics (NASDAQ:ORTX) initiated with Outperform rating and $27 (61% upside) price target at Cowen & Company. Initiated with Outperform rating at Wedbush. Initiated with Overweight rating at JPMorgan. Initiated with Neutral rating at Goldman Sachs. Cheerleaders cite the company's rare disease gene therapy pipeline. Wedbush's David Nierengarten says the company's four lead programs could generate peak sales of more than $2B.

Novartis (NYSE:NVS) upgraded to Outperform with a $100 (14% upside) price target at Cowen. Shares up 1% premarket.

Novavax (NASDAQ:NVAX) upgraded to Overweight with a $4 (133% upside) price target at Piper ahead of Phase 3 data on RSV vaccine ResVax and Phase 2 data on NanoFlu. Analyst Ed Tenthoff believes ResVax and NanoFlu could generate $1B and $1.4B, respectively, in sales by 2027. Shares up 10% premarket.

Eli Lilly (NYSE:LLY) downgraded to Neutral at Citigroup citing valuation. Shares down a fraction premarket.

Subscribe for full text news in your inbox